These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31221661)

  • 1. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.
    Shouval R; Fein JA; Shouval A; Danylesko I; Shem-Tov N; Zlotnik M; Yerushalmi R; Shimoni A; Nagler A
    Blood Adv; 2019 Jun; 3(12):1881-1890. PubMed ID: 31221661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
    Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
    Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Middeke JM; Kollinger F; Baldauf H; Stölzel F; Wermke M; von Bonin M; Sockel K; Link CS; Teipel R; Röllig C; Thiede C; Platzbecker U; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1947-1951. PubMed ID: 29793046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
    Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era.
    Salas MQ; Rodríguez-Lobato LG; Charry P; Suárez-Lledó M; Pedraza A; Solano MT; Arcarons J; Cid J; Lozano M; Rosiñol L; Esteve J; Carreras E; Fernández-Avilés F; Martínez C; Rovira M
    Hematol Transfus Cell Ther; 2023 Oct; ():. PubMed ID: 37891074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
    Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
    J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant.
    Fernández-Caballero M; Jiménez Lorenzo MJ; Morgades de la Fe M; Ferrà Coll C; Vives Polo S; Abril Sabater L; Navarro Ferrando JT; Ribera Santasusana JM
    Med Clin (Barc); 2022 May; 158(10):451-457. PubMed ID: 34404519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
    Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Ando T; Fujisawa S; Teshigawara H; Matsumura A; Sakuma T; Suzuki T; Teranaka H; Ogusa E; Ishii Y; Miyashita K; Takahashi H; Nakajima Y; Miyazaki T; Hagihara M; Matsumoto K; Yamazaki E; Nakajima H
    Int J Hematol; 2020 Jul; 112(1):46-56. PubMed ID: 32451786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of comorbidity indexes on non-relapse mortality.
    Xhaard A; Porcher R; Chien JW; de Latour RP; Robin M; Ribaud P; Rocha V; Devergie A; Ferry C; Martin PJ; Socié G
    Leukemia; 2008 Nov; 22(11):2062-9. PubMed ID: 18685612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.